Cargando…

Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis

BACKGROUND: The cardiovascular outcome trials (CVOTs) have shown that glucagon like peptide-1 receptor agonists (GLP1RAs) have varying degrees of cardiovascular (CV) safety in patients with type 2 diabetes mellitus (T2DM.) The lack of any head-to-head comparative trials among GLP1RAs urged the need...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alfayez, Osamah M., Almohammed, Omar A., Alkhezi, Omar S., Almutairi, Abdulaali R., Al Yami, Majed S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310317/ https://www.ncbi.nlm.nih.gov/pubmed/32571416 http://dx.doi.org/10.1186/s12933-020-01070-z

Ejemplares similares

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
por: Alkhatib, Nimer S., et al.
Publicado: (2022)

Incidence of Diabetic Ketoacidosis Among Pediatrics With Type 1 Diabetes Prior to and During COVID-19 Pandemic: A Meta-Analysis of Observational Studies
por: Alfayez, Osamah M., et al.
Publicado: (2022)

The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines
por: Alsubaie, Norah S., et al.
Publicado: (2021)

Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis
por: Altoukhi, Renad M, et al.
Publicado: (2020)

Parents' Hesitancy to Vaccinate Their 5–11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model
por: Almalki, Ohoud S., et al.
Publicado: (2022)

Corrigendum: Parents' Hesitancy to Vaccinate Their 5–11-Year-Old Children Against COVID-19 in Saudi Arabia: Predictors From the Health Belief Model
por: Almalki, Ohoud S., et al.
Publicado: (2022)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia
por: Alfayez, Osamah M., et al.
Publicado: (2022)

Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center
por: Korayem, Ghazwa B., et al.
Publicado: (2021)

Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies
por: Alshehri, Abdulmajeed M., et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

The impact of pharmacists providing direct patient care as members of interprofessional teams on diabetes management
por: Alfayez, Osamah M., et al.
Publicado: (2017)

Research barriers in Saudi pharmacy residency training programs
por: Alfayez, Osamah M., et al.
Publicado: (2023)

Impact of Thromboprophylaxis Intensity on Patients’ Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study
por: Almohareb, Sumaya N, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
por: Paul, Sanjoy K, et al.
Publicado: (2015)

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Characteristics of the ideal clinical pharmacy residency candidate: A survey of residency program directors and preceptors in Saudi Arabia
por: Alahmed, Abdullah A., et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

Indirect Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Peripheral Circadian Clocks in Mice
por: Ando, Hitoshi, et al.
Publicado: (2013)

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
por: Dawwas, Ghadeer K., et al.
Publicado: (2018)

Metformin use among obese patients with prediabetes in Qassim, Saudi Arabia: An observational study
por: Alfayez, Osamah M., et al.
Publicado: (2023)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
por: Song, Rui, et al.
Publicado: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
por: Cai, Xiaoling, et al.
Publicado: (2021)

Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
por: Chen, Jia-Jin, et al.
Publicado: (2022)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
por: Essien, Utibe R., et al.
Publicado: (2023)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists
por: Pattij, Tommy, et al.
Publicado: (2011)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Anti-Proliferative Activity of Glucagon-Like Peptide-1 Receptor Agonist on Obesity-Associated Breast Cancer: The Impact on Modulating Adipokines’ Expression in Adipocytes and Cancer Cells
por: Alanteet, Alaa A., et al.
Publicado: (2021)

The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review
por: Rahman, Ali, et al.
Publicado: (2023)

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2010)

Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States
por: Almohammed, Omar A., et al.
Publicado: (2022)

Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus
por: Huynh, Daniel J., et al.
Publicado: (2023)

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
por: Al Yami, Majed S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_btqbbnb8fc0hl7gn96l5kb4ctj